Recruiting

Aspirin and Preeclampsia

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

ClinicalTrials.gov IDNCT04479072

PhasePHASE4

Enrollment180

SponsorUniversity of Chicago

Age18 Years – 45 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Preeclampsia Postpartum

About this study

Interventions

Drug: Aspirin 81 mg — Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Drug: Placebo — Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.

Primary outcomes

Difference in Activin A levels (6 Months)
GLS percentages (6 months)

Eligibility information

Inclusion Criteria: 1. Pregnant Adults between 18 and 45 years of age 2. Diagnosed with preeclampsia 3. Presenting for delivery with a singleton gestation. Exclusion Criteria: 1. We will exclude patients in labor 2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation 3. Plan to deliver outside of the participating site 4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI. 5. Aspirin allergy 6. Clear indication for aspirin therapy or contraindication to aspirin therapy 7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders) 8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study. 9. Those who cannot provide consent

Study locations

University of Chicago Hospital, Chicago, Illinois 60637 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-28.